What type of study is this?

September 10, 2025PLoS MedicineOpen Access

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial

View Full Paper

Ask AI

Bookmark

The combination therapy achieved an objective response rate of 70.2% in patients with advanced breast cancer.
Participants experienced a median progression-free survival of 22.0 months, showcasing promising durability in treatment response.
The study involved 48 patients receiving dalpiciclib, pyrotinib, and endocrine therapy in a multicenter trial design.
With manageable safety, this chemotherapy-sparing approach may offer a viable alternative for advanced breast cancer patients.

No takes yet. Share an insight, caveat, or question.

Phase 2 trial demonstrated improved outcomes in ER-positive, HER2-positive advanced breast cancer, suggesting combination therapy's efficacy.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 2 trial demonstrated improved outcomes in ER-positive, HER2-positive advanced breast cancer, suggesting combination therapy's efficacy.